Sarit Assouline

2.4k total citations
37 papers, 866 citations indexed

About

Sarit Assouline is a scholar working on Molecular Biology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, Sarit Assouline has authored 37 papers receiving a total of 866 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 15 papers in Genetics and 15 papers in Pathology and Forensic Medicine. Recurrent topics in Sarit Assouline's work include Chronic Lymphocytic Leukemia Research (14 papers), Lymphoma Diagnosis and Treatment (14 papers) and Chronic Myeloid Leukemia Treatments (6 papers). Sarit Assouline is often cited by papers focused on Chronic Lymphocytic Leukemia Research (14 papers), Lymphoma Diagnosis and Treatment (14 papers) and Chronic Myeloid Leukemia Treatments (6 papers). Sarit Assouline collaborates with scholars based in Canada, United States and Germany. Sarit Assouline's co-authors include Wilson H. Miller, Caroline Rousseau, David Melnychuk, L. John Hoffer, Mark Levine, Line Robitaille, Kristopher A. Rosadiuk, Sebastian J. Padayatty, Samy Suissa and Sophie Dell’Aniello and has published in prestigious journals such as Nature, Journal of Clinical Oncology and Blood.

In The Last Decade

Sarit Assouline

33 papers receiving 839 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sarit Assouline Canada 12 349 280 254 195 105 37 866
Chan H. Park United States 14 351 1.0× 126 0.5× 167 0.7× 170 0.9× 22 0.2× 22 783
Mohsen Ghanefar United States 6 442 1.3× 84 0.3× 69 0.3× 267 1.4× 38 0.4× 8 1.1k
Ameen A. Salahudeen United States 12 393 1.1× 38 0.1× 114 0.4× 101 0.5× 107 1.0× 31 787
Ilaria Buondonno Italy 18 464 1.3× 88 0.3× 35 0.1× 181 0.9× 34 0.3× 23 965
Huan Qiao United States 14 244 0.7× 93 0.3× 176 0.7× 127 0.7× 16 0.2× 24 600
Kunishige Onuma Japan 18 349 1.0× 57 0.2× 50 0.2× 258 1.3× 28 0.3× 37 899
Gianfranca Corna Italy 13 319 0.9× 40 0.1× 71 0.3× 89 0.5× 145 1.4× 14 768
Young Yiul Lee South Korea 14 335 1.0× 147 0.5× 37 0.1× 185 0.9× 39 0.4× 27 722
Anita Söderberg Sweden 11 396 1.1× 137 0.5× 83 0.3× 49 0.3× 185 1.8× 18 798
A.C. Mamede Portugal 12 197 0.6× 61 0.2× 80 0.3× 65 0.3× 99 0.9× 20 806

Countries citing papers authored by Sarit Assouline

Since Specialization
Citations

This map shows the geographic impact of Sarit Assouline's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarit Assouline with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarit Assouline more than expected).

Fields of papers citing papers by Sarit Assouline

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarit Assouline. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarit Assouline. The network helps show where Sarit Assouline may publish in the future.

Co-authorship network of co-authors of Sarit Assouline

This figure shows the co-authorship network connecting the top 25 collaborators of Sarit Assouline. A scholar is included among the top collaborators of Sarit Assouline based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarit Assouline. Sarit Assouline is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Assouline, Sarit, Amitkumar Mehta, Walter Hanel, et al.. (2025). Phase I/II Study of Subasumstat (TAK-981) in Combination With Rituximab in Relapsed/Refractory Non-Hodgkin Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 25(11). 788–799.e11. 1 indexed citations
2.
3.
Osborne, Michael J., Biljana Culjkovic‐Kraljacic, Edward H. Ruediger, et al.. (2023). Medicinal Chemistry and NMR Driven Discovery of Novel UDP-glucuronosyltransferase 1A Inhibitors That Overcome Therapeutic Resistance in Cells. Journal of Molecular Biology. 436(2). 168378–168378. 3 indexed citations
4.
5.
Benoît, Alexandre, Melissa Lu, Vincent Luo, et al.. (2022). Mutated RAS-associating proteins and ERK activation in relapse/refractory diffuse large B cell lymphoma. Scientific Reports. 12(1). 779–779. 5 indexed citations
6.
Hébert, Josée, Lambert Busque, François Mercier, et al.. (2022). Blasts in context: the impact of the immune environment on acute myeloid leukemia prognosis and treatment. Blood Reviews. 57. 100991–100991. 14 indexed citations
7.
Morin, Ryan D., Sarah E. Arthur, & Sarit Assouline. (2021). Treating lymphoma is now a bit EZ-er. Blood Advances. 5(8). 2256–2263. 20 indexed citations
8.
Corpo, Olivier Del, et al.. (2021). Real-Life Use of Nilotinib for Chronic Phase CML Demonstrates Similar Efficacy and Rate of Cardiovascular Events As Enestnd. Blood. 138(Supplement 1). 4602–4602. 1 indexed citations
9.
Santiago, Raoul, Reza Forghani, Nikesh Muthukrishnan, et al.. (2021). CT-based radiomics model with machine learning for predicting primary treatment failure in diffuse large B-cell Lymphoma. Translational Oncology. 14(10). 101188–101188. 11 indexed citations
10.
11.
Pera, Benet, Jan Krumsiek, Sarit Assouline, et al.. (2018). Metabolomic Profiling Reveals Cellular Reprogramming of B-Cell Lymphoma by a Lysine Deacetylase Inhibitor through the Choline Pathway. EBioMedicine. 28. 80–89. 24 indexed citations
12.
Mistry, Pramod K., Elena Lukina, Hadhami Ben Turkia, et al.. (2017). Long-term results of ENGAGE: a phase 3, randomized, double‑blind, placebo-controlled, multi‑center study investigating the efficacy and safety of eliglustat in adults with type 1 Gaucher disease. Molecular Genetics and Metabolism. 120(1-2). S97–S98. 4 indexed citations
13.
Zahreddine, Hiba Ahmad, Biljana Culjkovic‐Kraljacic, Filippa Pettersson, et al.. (2017). The eukaryotic translation initiation factor eIF4E harnesses hyaluronan production to drive its malignant activity. eLife. 6. 16 indexed citations
14.
MacDonald, David, Anca Prica, Sarit Assouline, et al.. (2016). Emerging Therapies for the Treatment of Relapsed or Refractory Follicular Lymphoma. Current Oncology. 23(6). 407–417. 6 indexed citations
15.
Johnson, Nathalie A., Sarit Assouline, Miguel Alcaide, et al.. (2016). Abstract 117: Genetic landscapes of relapsed and refractory diffuse large B cell lymphomas. Cancer Research. 76(14_Supplement). 117–117. 1 indexed citations
16.
Zahreddine, Hiba Ahmad, Biljana Culjkovic‐Kraljacic, Sarit Assouline, et al.. (2014). The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation. Nature. 511(7507). 90–93. 149 indexed citations
17.
Nielsen, Torsten Holm, Nathalie A. Johnson, Lu Yao, et al.. (2013). Monitoring Response and Resistance to the Novel Arsenical Darinaparsin in an AML Patient. Frontiers in Pharmacology. 4. 9–9. 6 indexed citations
18.
Nielsen, Torsten Holm, Zuanel Diaz, Yao Lü, et al.. (2013). Abstract 64: Quality and feasibility of a protocol for simultaneous isolation of RNA, DNA and tissue for IHC from needle core lymph node biopsies in DLBCL adapted for multi-center trials.. Cancer Research. 73(8_Supplement). 64–64. 1 indexed citations
19.
Assouline, Sarit & Jeffrey H. Lipton. (2011). Monitoring Response and Resistance to Treatment in Chronic Myeloid Leukemia. Current Oncology. 18(2). 71–83. 29 indexed citations
20.
Opatrny, Lucie, Sophie Dell’Aniello, Sarit Assouline, & Samy Suissa. (2007). Hormone replacement therapy use and variations in the risk of breast cancer. BJOG An International Journal of Obstetrics & Gynaecology. 115(2). 169–175. 66 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chan H. Park Breakdown of academic impact, for papers by Mohsen Ghanefar Breakdown of academic impact, for papers by Ameen A. Salahudeen Breakdown of academic impact, for papers by Ilaria Buondonno Breakdown of academic impact, for papers by Huan Qiao Breakdown of academic impact, for papers by Kunishige Onuma Breakdown of academic impact, for papers by Gianfranca Corna Breakdown of academic impact, for papers by Young Yiul Lee Breakdown of academic impact, for papers by Anita Söderberg Breakdown of academic impact, for papers by A.C. Mamede
Rankless by CCL
2026